Exchange Traded Concepts
AUPH icon

Exchange Traded Concepts’s Aurinia Pharmaceuticals AUPH Stock Holding History

Exchange Traded Concepts’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1,570
Closed -$26.6K – 1745
2026
Q2 		$26.6K Sell
1,570
-57
-4% -$911 ﹤0.01% 1544
2026
Q1 		$24.1K Buy
+1,627
New +$23.8K ﹤0.01% 1478

Other funds holding AUPH

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
O'Shaughnessy Asset Management
O'Shaughnessy Asset Management Stamford, Connecticut $23.6B AUM 34.05% 1-Year Est. Return
Hillsdale Investment Management
Hillsdale Investment Management Toronto, Ontario, Canada $4.42B AUM 54.57% 1-Year Est. Return

Exchange Traded Concepts's AUPH Position: Q3 2026 in Review

Exchange Traded Concepts sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2026, closing a stake of 1,570 shares — an estimated $26.6K sold.

Exchange Traded Concepts first reported a position in AUPH in Q1 2026 and held it in 2 quarters. The position peaked at $26.6K in Q2 2026. 198 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

  • Exchange Traded Concepts reported no remaining Aurinia Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Exchange Traded Concepts sold 1,570 Aurinia Pharmaceuticals shares in Q3 2026, an estimated $26.6K.
  • Exchange Traded Concepts first reported a position in Aurinia Pharmaceuticals in Q1 2026 and held it in 2 quarters.
  • Exchange Traded Concepts's Aurinia Pharmaceuticals position peaked at $26.6K in Q2 2026.
  • 198 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on Exchange Traded Concepts's 13F filing for Q3 2026, filed 28 Oct 2026.